Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The researchers aimed to investigate the effect of point-of-care platelet function assay on
the periprocedural cardiac enzyme elevation in patients with diabetes mellitus.
All patients who are supposed to undergo coronary angiography were loaded with clopidogrel
(300mg) and aspirin (300mg) at D-1. If patients were determined to implant coronary stent
after diagnostic coronary angiography, their platelet function is assayed with Verifynow-ADP
(Accumetrics). If patients have >270 unit in the assay, they are randomized to abciximab or
control group. After successful stent implantation, cardiac enzymes (CK-MB, Troponin-I) are
followed at 8hr, 16hr and 24hr. Clinical outcomes including bleeding complications are
assessed at 1 month.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Bundang Hospital
Treatments:
Abciximab Antibodies, Monoclonal Aspirin Clopidogrel Immunoglobulin Fab Fragments